Baird analyst Jeff Johnson raised the firm’s price target on Insulet to $350 from $340 and keeps an Outperform rating on the shares. The analyst said Insulet delivered 45% yar-over-year growth in U.S. Omnipod revenue in 4Q on the heels of continued MDI share gains/competitive wins, and internal trade-ups.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PODD:
- Insulet reports Q4 adjusted EPS 55c, consensus 21c
- DexCom selloff on Apple article should be bought, says Oppenheimer
- Insulet acquires assets of Automated Glucose Control for $25M
- Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M
- Insulet initiated with a Peer Perform at Wolfe Research
